Effects of Obicetrapib, a Potent Oral CETP Inhibitor, on Alzheimer's Disease Biomarkers in 1727 Patients with cardiovascular disease
This very large biomarker study showed that obicetrapib significantly slowed the progression of AD biomarkers over a period of 1 year, particularly p -tau217 and p -tau217/Aβ42:Aβ40 ratio, with most pronounced effects in older individuals carrying the APOE4 allele. These findings support the dual therapeutic potential of obicetrapib in addressing both cardiovascular and neurodegenerative disorders. Given its effects on the early evolution of β-amyloid and tau pathology, obicetrapib represents a potential advancement in the prevention of AD, particularly in ApoE4 carriers who have an increased risks for both cardiovascular and AD pathologies.
Authors
- Andrew Caleb Hsieh (ORCID: https://orcid.org/0000-0002-0897-1050)
- MICHAEL SZAREK
- Douglas Kling
- Marc Ditmarsch (ORCID: https://orcid.org/0000-0002-2970-1893)
- Everard G.B. Vijverberg (ORCID: https://orcid.org/0000-0003-3879-884X)
- John Kastelein
- Michael Davidson
- Stephen Nicholls
- Kosh K Ray
- Philip Scheltens
Institutions
- Australian Centre for Heart Health (AU)
- Amsterdam University Medical Centers (NL)
- Enceladus Pharmaceuticals (Netherlands) (NL)
- Imperial College London (GB)
- University of Colorado Anschutz Medical Campus (US)
- Monash University (AU)
- Vrije Universiteit Amsterdam (NL)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70861_108443
- Primary Topic
- Cholesterol and Lipid Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00